Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Reply to "Phosphorylation of G3BP1-S149 does not influence stress granule assembly".

Tourrière H, Tazi J.

J Cell Biol. 2019 Jul 1;218(7):2433-2434. doi: 10.1083/jcb.201905105. Epub 2019 Jun 6.

PMID:
31171633
2.
3.

Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing.

Vautrin A, Manchon L, Garcel A, Campos N, Lapasset L, Laaref AM, Bruno R, Gislard M, Dubois E, Scherrer D, Ehrlich JH, Tazi J.

Sci Rep. 2019 Jan 28;9(1):792. doi: 10.1038/s41598-018-37813-y.

4.

RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation.

Manchon L, Chebli K, Papon L, Paul C, Garcel A, Campos N, Scherrer D, Ehrlich H, Hahne M, Tazi J.

Sci Data. 2017 Oct 17;4:170150. doi: 10.1038/sdata.2017.150.

5.

Reversing HIV latency via sphingosine-1-phosphate receptor 1 signaling.

Duquenne C, Gimenez S, Guigues A, Viala B, Boulouis C, Mettling C, Maurel D, Campos N, Doumazane E, Comps-Agrar L, Tazi J, Prézeau L, Psomas C, Corbeau P, François V.

AIDS. 2017 Nov 28;31(18):2443-2454. doi: 10.1097/QAD.0000000000001649.

PMID:
28926402
6.

The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages.

Chebli K, Papon L, Paul C, Garcel A, Campos N, Scherrer D, J Ehrlich H, Hahne M, Tazi J.

Sci Rep. 2017 Jul 7;7(1):4860. doi: 10.1038/s41598-017-04071-3.

7.

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.

Steens JM, Scherrer D, Gineste P, Barrett PN, Khuanchai S, Winai R, Ruxrungtham K, Tazi J, Murphy R, Ehrlich H.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00545-17. doi: 10.1128/AAC.00545-17. Print 2017 Jul.

8.

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.

Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.

J Antimicrob Chemother. 2017 Mar 1;72(3):820-828. doi: 10.1093/jac/dkw458.

PMID:
27999038
9.

Pharmacological modulation of LMNA SRSF1-dependent splicing abrogates diet-induced obesity in mice.

Santo J, Lopez-Herrera C, Apolit C, Bareche Y, Lapasset L, Chavey C, Capozi S, Mahuteau-Betzer F, Najman R, Fornarelli P, Lopez-Mejía IC, Béranger G, Casas F, Amri EZ, Pau B, Scherrer D, Tazi J.

Int J Obes (Lond). 2017 Mar;41(3):390-401. doi: 10.1038/ijo.2016.220. Epub 2016 Dec 5.

PMID:
27916986
10.

Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.

Scherrer D, Rouzier R, Cardona M, Barrett PN, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01288-16. doi: 10.1128/AAC.01288-16. Print 2017 Jan.

11.

Preferential binding of a stable G3BP ribonucleoprotein complex to intron-retaining transcripts in mouse brain and modulation of their expression in the cerebellum.

Martin S, Bellora N, González-Vallinas J, Irimia M, Chebli K, de Toledo M, Raabe M, Eyras E, Urlaub H, Blencowe BJ, Tazi J.

J Neurochem. 2016 Nov;139(3):349-368. doi: 10.1111/jnc.13768. Epub 2016 Oct 18.

12.

Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.

Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES, Mahuteau-Betzer F, Najman R, Fornarelli P, Tantale K, Basyuk E, Séveno M, Venables JP, Pau B, Bertrand E, Wainberg MA, Speck RF, Scherrer D, Tazi J.

Retrovirology. 2015 Apr 9;12:30. doi: 10.1186/s12977-015-0159-3.

13.

A role for the serine/arginine-rich (SR) protein B52/SRSF6 in cell growth and myc expression in Drosophila.

Fernando C, Audibert A, Simon F, Tazi J, Juge F.

Genetics. 2015 Apr;199(4):1201-11. doi: 10.1534/genetics.115.174391. Epub 2015 Feb 12.

14.

Visualization of G3BP stress granules dynamics in live primary cells.

Martin S, Tazi J.

J Vis Exp. 2014 May 21;(87). doi: 10.3791/51197.

15.

Antagonistic functions of LMNA isoforms in energy expenditure and lifespan.

Lopez-Mejia IC, de Toledo M, Chavey C, Lapasset L, Cavelier P, Lopez-Herrera C, Chebli K, Fort P, Beranger G, Fajas L, Amri EZ, Casas F, Tazi J.

EMBO Rep. 2014 May;15(5):529-39. doi: 10.1002/embr.201338126. Epub 2014 Mar 17.

16.

MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation.

Venables JP, Lapasset L, Gadea G, Fort P, Klinck R, Irimia M, Vignal E, Thibault P, Prinos P, Chabot B, Abou Elela S, Roux P, Lemaitre JM, Tazi J.

Nat Commun. 2013;4:2480. doi: 10.1038/ncomms3480.

PMID:
24048253
17.

The sirtuin SIRT6 regulates stress granule formation in C. elegans and mammals.

Jedrusik-Bode M, Studencka M, Smolka C, Baumann T, Schmidt H, Kampf J, Paap F, Martin S, Tazi J, Müller KM, Krüger M, Braun T, Bober E.

J Cell Sci. 2013 Nov 15;126(Pt 22):5166-77. doi: 10.1242/jcs.130708. Epub 2013 Sep 6.

18.

Tissue-specific and SRSF1-dependent splicing of fibronectin, a matrix protein that controls host cell invasion.

Lopez-Mejia IC, De Toledo M, Della Seta F, Fafet P, Rebouissou C, Deleuze V, Blanchard JM, Jorgensen C, Tazi J, Vignais ML.

Mol Biol Cell. 2013 Oct;24(20):3164-76. doi: 10.1091/mbc.E13-03-0142. Epub 2013 Aug 21.

19.

Deficiency of G3BP1, the stress granules assembly factor, results in abnormal synaptic plasticity and calcium homeostasis in neurons.

Martin S, Zekri L, Metz A, Maurice T, Chebli K, Vignes M, Tazi J.

J Neurochem. 2013 Apr;125(2):175-84. doi: 10.1111/jnc.12189. Epub 2013 Mar 6.

20.

RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues.

Venables JP, Brosseau JP, Gadea G, Klinck R, Prinos P, Beaulieu JF, Lapointe E, Durand M, Thibault P, Tremblay K, Rousset F, Tazi J, Abou Elela S, Chabot B.

Mol Cell Biol. 2013 Jan;33(2):396-405. doi: 10.1128/MCB.01174-12. Epub 2012 Nov 12.

21.

Revisiting G3BP1 as a RasGAP binding protein: sensitization of tumor cells to chemotherapy by the RasGAP 317-326 sequence does not involve G3BP1.

Annibaldi A, Dousse A, Martin S, Tazi J, Widmann C.

PLoS One. 2011;6(12):e29024. doi: 10.1371/journal.pone.0029024. Epub 2011 Dec 19.

22.

Splicing-directed therapy in a new mouse model of human accelerated aging.

Osorio FG, Navarro CL, Cadiñanos J, López-Mejía IC, Quirós PM, Bartoli C, Rivera J, Tazi J, Guzmán G, Varela I, Depetris D, de Carlos F, Cobo J, Andrés V, De Sandre-Giovannoli A, Freije JM, Lévy N, López-Otín C.

Sci Transl Med. 2011 Oct 26;3(106):106ra107. doi: 10.1126/scitranslmed.3002847.

23.

Regulated functional alternative splicing in Drosophila.

Venables JP, Tazi J, Juge F.

Nucleic Acids Res. 2012 Jan;40(1):1-10. doi: 10.1093/nar/gkr648. Epub 2011 Sep 8. Review.

24.

A conserved splicing mechanism of the LMNA gene controls premature aging.

Lopez-Mejia IC, Vautrot V, De Toledo M, Behm-Ansmant I, Bourgeois CF, Navarro CL, Osorio FG, Freije JM, Stévenin J, De Sandre-Giovannoli A, Lopez-Otin C, Lévy N, Branlant C, Tazi J.

Hum Mol Genet. 2011 Dec 1;20(23):4540-55. doi: 10.1093/hmg/ddr385. Epub 2011 Aug 29.

PMID:
21875900
25.

Tissue-specific alternative splicing of Tak1 is conserved in deuterostomes.

Venables JP, Vignal E, Baghdiguian S, Fort P, Tazi J.

Mol Biol Evol. 2012 Jan;29(1):261-9. doi: 10.1093/molbev/msr193. Epub 2011 Aug 27.

PMID:
21873631
26.

Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives.

Ghigna C, De Toledo M, Bonomi S, Valacca C, Gallo S, Apicella M, Eperon I, Tazi J, Biamonti G.

RNA Biol. 2010 Jul-Aug;7(4):495-503. Epub 2010 Jul 1.

PMID:
20864806
27.

The SR protein B52/SRp55 is required for DNA topoisomerase I recruitment to chromatin, mRNA release and transcription shutdown.

Juge F, Fernando C, Fic W, Tazi J.

PLoS Genet. 2010 Sep 16;6(9):e1001124. doi: 10.1371/journal.pgen.1001124.

28.

Exon definition complexes contain the tri-snRNP and can be directly converted into B-like precatalytic splicing complexes.

Schneider M, Will CL, Anokhina M, Tazi J, Urlaub H, Lührmann R.

Mol Cell. 2010 Apr 23;38(2):223-35. doi: 10.1016/j.molcel.2010.02.027.

29.

Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis.

Dutertre M, Lacroix-Triki M, Driouch K, de la Grange P, Gratadou L, Beck S, Millevoi S, Tazi J, Lidereau R, Vagner S, Auboeuf D.

Cancer Res. 2010 Feb 1;70(3):896-905. doi: 10.1158/0008-5472.CAN-09-2703. Epub 2010 Jan 26.

30.

Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action.

Tazi J, Bakkour N, Marchand V, Ayadi L, Aboufirassi A, Branlant C.

FEBS J. 2010 Feb;277(4):867-76. doi: 10.1111/j.1742-4658.2009.07522.x. Epub 2010 Jan 15. Review.

31.

Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription.

Tuduri S, Crabbé L, Conti C, Tourrière H, Holtgreve-Grez H, Jauch A, Pantesco V, De Vos J, Thomas A, Theillet C, Pommier Y, Tazi J, Coquelle A, Pasero P.

Nat Cell Biol. 2009 Nov;11(11):1315-24. doi: 10.1038/ncb1984. Epub 2009 Oct 18. Erratum in: Nat Cell Biol. 2010 Nov;12(11):1122.

32.

Protection against retrovirus pathogenesis by SR protein inhibitors.

Keriel A, Mahuteau-Betzer F, Jacquet C, Plays M, Grierson D, Sitbon M, Tazi J.

PLoS One. 2009;4(2):e4533. doi: 10.1371/journal.pone.0004533. Epub 2009 Feb 19.

33.

Alternative splicing and disease.

Tazi J, Bakkour N, Stamm S.

Biochim Biophys Acta. 2009 Jan;1792(1):14-26. doi: 10.1016/j.bbadis.2008.09.017. Epub 2008 Oct 17. Review.

34.

A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects.

Tournier I, Vezain M, Martins A, Charbonnier F, Baert-Desurmont S, Olschwang S, Wang Q, Buisine MP, Soret J, Tazi J, Frébourg T, Tosi M.

Hum Mutat. 2008 Dec;29(12):1412-24. doi: 10.1002/humu.20796.

PMID:
18561205
35.

A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking.

Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, Jariel-Encontre I, Piechaczyk M, Bertrand E, Tazi J, Coux O.

Mol Biol Cell. 2008 Apr;19(4):1706-16. doi: 10.1091/mbc.E07-07-0637. Epub 2008 Feb 6.

36.

Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance.

Bakkour N, Lin YL, Maire S, Ayadi L, Mahuteau-Betzer F, Nguyen CH, Mettling C, Portales P, Grierson D, Chabot B, Jeanteur P, Branlant C, Corbeau P, Tazi J.

PLoS Pathog. 2007 Oct 26;3(10):1530-9.

37.

Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies.

Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, Bertrand E, Tazi J, Lejeune F.

J Cell Biol. 2007 Sep 24;178(7):1145-60.

38.
39.

The SR family proteins B52 and dASF/SF2 modulate development of the Drosophila visual system by regulating specific RNA targets.

Gabut M, Dejardin J, Tazi J, Soret J.

Mol Cell Biol. 2007 Apr;27(8):3087-97. Epub 2007 Feb 5.

40.

SR proteins as potential targets for therapy.

Soret J, Gabut M, Tazi J.

Prog Mol Subcell Biol. 2006;44:65-87. Review.

PMID:
17076265
41.

[Alternative splicing: a novel pharmacological target with wide therapeutic potential].

Jeanteur P, Tazi J.

Bull Acad Natl Med. 2005 May;189(5):949-59; discussion 959-61. Review. French.

PMID:
16433465
42.

[Selective modification of alternative splicing by indole derivatives that target SR protein splicing factors].

Jeanteur P, Tazi J.

Med Sci (Paris). 2005 Oct;21(10):793-5. French. No abstract available.

43.

Control of fetal growth and neonatal survival by the RasGAP-associated endoribonuclease G3BP.

Zekri L, Chebli K, Tourrière H, Nielsen FC, Hansen TV, Rami A, Tazi J.

Mol Cell Biol. 2005 Oct;25(19):8703-16.

44.

The spliceosome: a novel multi-faceted target for therapy.

Tazi J, Durand S, Jeanteur P.

Trends Biochem Sci. 2005 Aug;30(8):469-78. Review.

PMID:
16009556
45.

Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors.

Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, Fic W, Divita G, Rivalle C, Dauzonne D, Nguyen CH, Jeanteur P, Tazi J.

Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8764-9. Epub 2005 Jun 6.

46.
47.

Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives.

Tazi J, Bakkour N, Soret J, Zekri L, Hazra B, Laine W, Baldeyrou B, Lansiaux A, Bailly C.

Mol Pharmacol. 2005 Apr;67(4):1186-94. Epub 2004 Dec 29.

PMID:
15625279
48.
49.

Regulation of cytoplasmic stress granules by apoptosis-inducing factor.

Candé C, Vahsen N, Métivier D, Tourrière H, Chebli K, Garrido C, Tazi J, Kroemer G.

J Cell Sci. 2004 Sep 1;117(Pt 19):4461-8. Epub 2004 Aug 17.

50.

Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells.

Solier S, Lansiaux A, Logette E, Wu J, Soret J, Tazi J, Bailly C, Desoche L, Solary E, Corcos L.

Mol Cancer Res. 2004 Jan;2(1):53-61.

Supplemental Content

Support Center